Abstract. Reports indicate that, even in KRAS-mutated colon cancer, there are subsets of patients who benefit from anti-EGFR monoclonal antibody (MoAb) treatment. The aim of the present study was to identify genetic profiles that contribute to the responsiveness of metastatic colorectal cancer (mCRC) to anti-EGFR MoAb. We retrospectively evaluated the efficacy of anti-EGFR MoAb in mCRC patients with KRAS mutations according to KRAS mutational subtypes, BRAF and PIK3CA mutational status and PTEN and MET expression. Among 21 patients with KRAS-mutant tumors, 8 (38%) harbored p.G13D, 7 (33%) harbored p.G12V, 5 (24%) harbored p.G12D, and 1 (5%) harbored p.G12C mutation. Patients with the p.G13D mutation exhibited a significantly higher disease control rate than patients with other KRAS mutations (P=0.042), and tended to show a longer progression-free survival (PFS) than patients with other KRAS mutations with marginal significance (P= 0.074). Patients with loss of PTEN had significantly shorter PFS than those with normal PTEN expression in patients with KRAS mutations (P=0.044). MET overexpression was significantly associated with shorter PFS compared to normal MET expression in patients with KRAS mutations (P=0.016). Our data demonstrated the potential utility of alterations in PTEN and MET expression as predictive markers for response to anti-EGFR MoAbs in mCRC patients with KRAS mutations. In addition, we confirmed the predictive value of the KRAS p.G13D mutation for better response to anti-EGFR therapies in comparison with other KRAS mutations.
Introduction
During the last decade, several clinical studies have confirmed that targeting the epidermal growth factor receptor (EGFR) with specific monoclonal antibodies (MoAbs) may improve the outcome of metastatic colorectal carcinoma (mCRC) patients (1, 2) . Mutations of the KRAS oncogene, an important intracellular signaling molecule downstream of EGFR, have been identified as a strong negative predictor for response to anti-EGFR-based therapies (3) (4) (5) . As a consequence, mutation testing of KRAS has become mandatory for the approval for the use of cetuximab and panitumumab in the treatment of mCRC by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Japanese Ministry of Health, Labour and Welfare (MHLW) (3, 6, 7) . Hence, only mCRC patients with confirmed KRAS wild-type status are currently eligible for therapies using anti-EGFR antibodies in many countries.
On the other hand, reports indicate that, even in KRASmutated colon cancer, there are subsets of patients who benefit from anti-EGFR antibody treatment (8) (9) (10) . These studies suggest that all KRAS mutations are not equivalent in their biological characteristics. First, an in vitro study revealed that cells with KRAS codon-13 mutations (mainly the p.G13D mutation) exhibit weaker transforming activity than those with codon-12 mutations (3, 11) . Second, a subset of patients presenting with tumors with KRAS mutations, particularly the p.G13D mutation, responded to anti-EGFR treatment (8) (9) (10) . Furthermore, in a recent meta-analysis using a pooled data set of 579 patients with chemotherapy-refractory colon carcinoma, the p.G13D mutation was reported to have predictive value for the treatment of mCRC with cetuximab (12) . These findings indicate that anti-EGFR antibodies may have a stronger effect on tumors with the KRAS p.G13D mutation than those with other KRAS mutations. However, several studies did not detect a significant survival advantage in patients with p.G13D-mutated tumors treated with cetuximab monotherapy (13, 14) . Therefore, the impact of the subtype of KRAS mutation on responsiveness to anti-EGFR therapies remains uncertain.
A second critical aspect of EGFR-targeted therapies comes from the presence of other genetic abnormalities that can affect responses to such therapies in KRAS wild-type patients. Even in a KRAS wild-type group, less than 50% of patients responded to EGFR-targeted therapy (4, 5, 15) . These observations have prompted investigators to analyze the involvement in mCRC of other genes of the RAS/RAF/MAPK and PI3K/PTEN/Akt pathways. In this regard, the presence of oncogenic deregulation of EGFR and other members of its downstream signaling pathways, such as BRAF, PIK3CA, and PTEN, have been shown to influence the responsiveness to cetuximab and panitumumab and could, therefore, help to identify non-responder patients (4, 5, (15) (16) (17) . Furthermore, recent studies also have suggested that activation of MET, a tyrosine kinase that acts as a receptor for hepatocyte growth factor (HGF) and can activate the RAS/RAF/MAPK and PTEN/PI3K/Akt pathways, may be a novel mechanism of cetuximab resistance in CRC (18) (19) (20) . However, no studies have yet addressed whether these additional aberrations may influence the responsiveness to anti-EGFR MoAb therapies in KRAS-mutated mCRC, mostly because these MoAb therapies are currently not recommended for this type of mCRC.
In the present study, we enrolled mCRC patients with KRAS mutations who had been treated with anti-EGFR MoAbs before the start of such restrictions for this therapy. Retrospective analyses of these patients enabled us to evaluate the impact of KRAS mutation subtype, together with additional aberrations in other EGFR downstream genes, on the efficacy of anti-EGFR MoAb therapies in mCRCs with mutant KRAS. In addition to evaluating the association between the types of KRAS mutations and the therapeutic efficacy of anti-EGFR therapies, we investigated whether PTEN or MET expression and BRAF or PIK3CA mutation might influence the outcome in KRAS-mutant patients with mCRC treated by anti-EGFR MoAbs. Our final goal was to identify a group of patients which will benefit from such treatment among KRAS-mutant patients with mCRC.
Patients and methods

Patients.
The clinical outcome of anti-EGFR MoAb therapy was retrospectively analyzed for possible associations with the molecular features of tumors in the mCRC patients. This study enrolled 81 Japanese patients who were treated at the Department of Gastroenterological Surgery and Medical Oncology, Kyorin University Hospital, between November 2008 and March 2012. All patients presented with histologically confirmed mCRC, and had been treated with salvage chemotherapy incorporating cetuximab or panitumumab. Clinical features of the patients and pathological profiles of the tumors were obtained from patient medical records. Cetuximab, as monotherapy or in combination with irinotecan, was administered intravenously (i.v.) at a loading dose of 400 mg/m 2 over 2 h, followed by weekly doses administered at 250 mg/m 2 over 1 h. Panitumumab was administered i.v. every 2 weeks at a dose of 6 mg/kg. Treatment was continued until disease progression (PD) or toxicity occurred. Clinical evaluation and tumor response were analyzed according to Response Evaluation Criteria in Solid Tumors (RECIST) (21) . Genetic alterations (subtype of KRAS mutation, mutations of BRAF and PIK3CA, loss of PTEN expression and MET overexpression) were retrospectively investigated in patient tumor specimens as described below, and the association with the response to anti-EGFR MoAb therapies was analyzed in patients with mutant KRAS. This study was approved by the Research Ethics Committee of Kyorin University School of Medicine Hospital.
Mutational analysis of KRAS, BRAF and PIK3CA by direct sequencing. Paraffin-embedded tissues (primary or metastatic) were sectioned at 10-µm thicknesses and mounted as three separate slides per tissue. The resulting slides were treated three times with xylene and then washed with ethanol. To minimize contamination by normal DNA, areas in which at least 70% of the cells exhibited disease-specific pathology were dissected under a binocular microscope; DNA was extracted from the dissected tissues using the QIAamp FFPE Tissue kit (Qiagen). Segments of the KRAS, BRAF and PIK3CA genes were amplified using gene-specific primers and subjected to direct DNA sequencing as previously described (15, 22) . KRAS sequences were screened for point mutations in codons 12 and 13 within exon 2, two hotspots that cumulatively include >95% of mutations in this gene (4, 5, 15) . BRAF sequences were screened for V600E mutations within exon 15, a site at which >95% of point mutations in this gene occur (5, 15) . PIK3CA sequences were screened for mutations within exons 9 and 20, sites at which >80% of point mutations in this gene occur (17) .
Immunohistochemistry of PTEN and MET. PTEN and MET expression levels were evaluated by immunohistochemistry performed on 4-µm tissue sections of paraffin-embedded specimens. PTEN was assessed using the 17.A mouse MoAb (1:25 dilution; Neomarkers, Thermo Fisher Scientific Inc., Fremont, CA, USA); MET was assessed using the SP44 rabbit MoAb (Spring Biosciences, Pleasanton, CA, USA) (23, 24) . Negative controls were incubated with nonimmune solution instead of the primary antibody. Endothelial and hepatocellular carcinoma cells were used as positive controls for PTEN and MET expression, respectively. The PTEN and MET staining intensities were evaluated by a pathologist (Y.O.) who was blinded to the diagnosis of the individual patients.
To our knowledge, there currently are no validated scoring systems for interpretation of PTEN or MET staining intensity. Both PTEN and MET are localized primarily in the cytoplasm (4,25); we therefore adopted a scoring system that has been used for other cytoplasmic proteins and is based on the intensity of immunoreactivity and the percentage of stained cells (26) (27) (28) . Specifically, intensity was scored according to a four-tier system: 0, no staining; 1, weak; 2, moderate; and 3, strong. An additional 1, 2, or 3 points were assigned depending in whether the percentage of positive cells was <25%, 25-50% or >50%, respectively (4, 5) .
We defined normal PTEN expression as a score of ≥4 (Fig. 1A) ; scores of 0-3 were classified as loss of expression (Fig. 1B) . We defined normal/low expression of MET as a score of 0-3 (Fig. 1C) ; scores of ≥4 were classified as MET overexpression (Fig. 1D ).
Statistical analysis.
Comparison of categorical variables was performed with the χ 2 test or the Fisher's exact test. The progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method. Comparisons between different groups were performed using log-rank tests.
Two-tailed P-values of <0.05 were considered significant. All analyses were performed using SPSS software (SPSS for Windows version 15.0; SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics.
Among the 81 patients enrolled in the study, 65 patients were able to be analyzed for all of the molecular parameters examined (mutations of KRAS, BRAF and PIK3CA, and expression of PTEN and MET). These 65 patients comprised 49 men and 16 women with a mean age of 68 years (range, 38 to 85 years). Among these 65 patients, the response rate (RR) and the disease control rate (DCR) were 23 and 51%, respectively, and PFS and OS were 3.5 and 11.9 months, respectively.
The mutations in KRAS exon 2 were detected in 21 (32%) of the 65 patients. Table Ⅰ summarizes the characteristics of the 21 patients who harbored tumors with mutant KRAS genes. These 21 patients comprised 14 men and 7 women with a mean age of 67 years (range, 38 to 82 years). At a median follow-up of 5.2 months (range, 1.7-24.4 months), disease had progressed in all patients with KRAS mutations, and 16 (70%) patients had died. In this 21-patient group, we observed no patients with complete response (CR) and partial response (PR), 3 with stable disease (SD) and 18 with progressive disease (PD). Therefore, the overall RR was 0%, and the DCR was 14%. RR and DCR were significantly lower in patients with KRAS mutations than in those with wild-type KRAS: for RR, the values were 0 vs. 34% (P<0.001); for DCR, the values were 14 vs. 68% (P<0.001). Median PFS and OS were significantly shorter in patients whose tumors carried KRAS mutations than in those without mutations (PFS: 1.8 vs. 5.9 months, P<0.001; OS: 5.5 vs. 15.4 months; P=0.023).
Analysis of KRAS mutation subtypes.
Among the 21 patients with KRAS-mutant tumors, 8 (38%) harbored p.G13D, 7 (33%) harbored p.G12V, 5 (24%) harbored p.G12D, and 1 (5%) harbored p.G12C mutation (Table Ⅰ) . Patients with the p.G13D mutation exhibited significantly higher DCR than patients with other KRAS mutations (P=0.042), but no significant difference in DCR compared to wild-type KRAS patients was noted (P=0.124) (Table ⅡA) . Regarding RR, patients with p.G13D showed no significant difference compared to patients with other KRAS mutations or wild-type KRAS (Table ⅡA) .
Patients with the p.G13D mutation tended to have a prolonged PFS than patients with other KRAS mutations, and the difference was marginally significant. (2.1 vs. 1.7 months; HR, 1.52; 95% CI, 0.95-2.59; P=0.074; Table ⅡB, Fig. 2A ). No significant correlation was detected between the subtype of KRAS mutation and OS (Fig. 2B ).
BRAF and PIK3CA mutational analysis. As expected from the reported exclusivity between KRAS and BRAF mutations (15), BRAF mutation was not detected among patients with KRAS mutations; therefore, the impact of the BRAF mutation could not be analyzed in this patient group (Table Ⅲ) . PIK3CA mutations were detected in 3 (14%) of the 21 patients with KRAS mutations (Table Ⅲ) . No significant correlation was found between the PIK3CA mutational status and the subtype of KRAS mutation. None of the PIK3CA-mutant patients exhibited a response to anti-EGFR MoAb therapy. However, the difference in DCR between patients with and without PIK3CA mutation was not statistically significant (P=0.612; 2.0 months; HR, 1.61; 95% CI, 0.98-2.69; P=0.044, Fig. 3C ), although no significant association between levels of PTEN expression and RR, DCR or OS was detected in patients with mutant KRAS (Table ⅣA and B, Fig. 3D ).
MET immunohistochemical evaluation.
Overexpression of MET was detected in 10 (48%) of the 21 patients with KRAS mutations. No significant correlation was found between MET expression status and the subtype of KRAS mutation (Table Ⅲ) . MET overexpression was significantly associated with shorter PFS compared to normal MET expression (1.7 vs. 2.0 months; HR, 1.69; 95% CI, 1.02-2.85; P=0.016, Fig. 3E ), although no significant association between levels of MET expression and RR, DCR, or OS was noted in patients with mutant KRAS (Table ⅣA and B, Fig. 3F ).
Multi-gene analysis. The results described above suggested that KRAS p.G13D mutation and normal PTEN and MET . The PFS of these 2 patients were similar to the PFS of patients with wild-type KRAS (median; 5.9 months, 95% CI, 3.5-7.3 months).
KRAS ------------------------------------------------------------------
Discussion
Since anti-EGFR MoAb therapies are currently restricted to patients with wild-type KRAS in many countries, few data are available regarding the response to these therapies in mCRC patients with mutant KRAS. To the best of our knowledge, the research presented here represents the first study to analyze associations among subtypes of KRAS, additional genetic alterations, and efficacy of anti-EGFR MoAb therapies in mCRC patients with KRAS mutations. The most striking finding in this study was the fact that loss of PTEN expression and MET overexpression was associated with reduced PFS even in patients with KRAS mutations. PTEN is a tumor-suppressor protein that regulates the PI3K/ Akt signal transduction pathway. Loss of PTEN production is associated with intrinsic activation of the Akt pathway, conferring resistance to inhibitors of the HER family (29) . Accordingly, low PTEN expression has been associated with lack of response to anti-EGFR MoAbs in several reports (4, 5) , although such a correlation was not reported by other researchers (16, 18) . In these earlier analyses, the presence of KRAS mutations was not specified, precluding recognition of such an association in patients with KRAS-mutated mCRCs.
MET is an oncogene that contains a tyrosine kinase domain and can activate the RAS/RAF/MAPK and PTEN/PI3K/Akt pathways by itself or via EGFR transphosphorylation (19,30) . MET reportedly is involved in many mechanisms of cancer proliferation and metastasis. MET additionally contributes to cancer resistance to EGFR inhibitors through bypass signaling. In CRC, overexpression of MET has been suggested to be associated with tumor progression (31, 32) . Subsequent studies have indicated an association of MET overexpression with poor outcome of mCRCs, including inferior response to anti-EGFR therapy (18) . However, as with PTEN above, these studies did not separately analyze patients with KRAS mutations. Our present data regarding PTEN and MET indicate that mCRC patients lacking MET overexpression or loss of PTEN may show some benefit by these therapies even if these patients harbor KRAS mutations in their tumors. DCR also was inferior in patients with these molecular aberrations, although the difference fell short of statistical significance. These results suggest that the policies restricting anti-EGFR MoAb therapies to mCRC patients with wild-type KRAS might deprive some patients who would benefit from such treatments. Assessment of genetic alterations in EGFR signaling pathways other than KRAS may enable physicians to identify patients who would benefit from anti-EGFR treatment despite the presence of KRAS mutations.
Several lines of evidence also indicate that KRAS p.G13D-mutated CRC defines a less aggressive phenotype and is more sensitive to anti-EGFR treatment than codon-12 mutated CRC. While mutations in either codons 12 or 13 affect the intrinsic GTPase activity of the KRAS protein, structural and functional analyses demonstrated that the glycine residue at position 12 is more critical for function of wild-type KRAS than the glycine at position 13 (33) . In addition, transfection of NIH3T3 cells with KRAS mutated in codon 12 resulted in a more aggressive phenotype than that observed in cells transfected with KRAS harboring the codon-13 mutation (11) . In accordance with these observations, several clinical studies have revealed that the tumors from patients who responded to anti-EGFR therapies predominantly harbored codon-13 mutations, and all codon-13 mutant responders carried the p.G13D mutation (11) (12) (13) . More importantly, 3 meta-analyses have indicated that patients with the p.G13D mutation who received cetuximab showed a better response to cetuximab than patients with KRAS codon-12 mutations (10, 12, 34) . In these analyses, the p.G13D mutation was associated with longer PFS and OS of patients treated with a combination of cetuximab plus chemotherapy compared to other KRAS mutations. The present study is, to our knowledge, the first study conducted in a single institute to clarify the association of the p.G13D mutation with superior clinical response (DCR) to anti-EGFR MoAbs in mCRC patients. In fact, patients with the p.G13D mutation exhibited DCR equivalent to those with wild-type KRAS. Lack of statistical significance in the prolonging of PFS in patients with p.G13D may be due in part to the small sample size in our study. Although meta-analysis is generally considered to provide higher levels of confidence than single studies, the present study (involving patients treated by relatively uniform therapies in a single institute) reinforces the results observed in meta-analyses. These observations should prompt further clinical trials to investigate whether mCRC patients with p.G13D might benefit from anti-EGFR MoAb therapies.
In testing molecular biomarkers as predictors of therapeutic responses, multi-gene models have been proposed to be superior to single-gene models (5, 16) . The present study could not precisely analyze the feasibility of multi-gene models, because the sample size was small. However, as described above, incorporation of multiple factors (p.G13D, normal PTEN and MET expression) appeared to identify patients who showed the best response to anti-EGFR therapies. These results suggest that PTEN and MET expression levels, together with subtype of KRAS mutation, might be candidate criteria for the selection of KRAS-mutant patients expected to exhibit favorable responses to anti-EGFR MoAbs. The incorporation of PTEN, MET and subtypes of KRAS mutation into the design of clinical trials may permit further individualization of treatment for mCRC by helping to define true predictive markers (20) . If these data are confirmed in future large studies, KRAS-mutated mCRC patients having these molecular features might be eligible for anti-EGFR MoAb therapy before trials of treatment by novel therapeutic drugs for mCRC, such as regorafenib or aflibercept (35, 36) .
The present study has some limitations. Notably, our study was performed retrospectively in a relatively small and heterogeneous population. The small sample size may have contributed to lack of statistical significance in some analyses. The majority of our population (90%) was treated with two or more chemotherapy regimens before anti-EGFR MoAb therapy. Additionally, the anti-EGFR treatment protocols were heterogeneous. Our findings therefore require further validation in subsequent prospective studies prior to application in the clinical practice.
In conclusion, our data demonstrated the potential utility of alterations in PTEN and MET expression as predictive markers for response to anti-EGFR MoAbs in mCRC patients with KRAS mutations. In addition, we confirmed the predictive value of the KRAS p.G13D mutation for better response to anti-EGFR therapies in comparison with other KRAS mutations. Thus, a subset of mCRC patients with KRAS mutations who harbor specific additional molecular features exhibited responsiveness to anti-EGFR MoAb treatment that was equivalent to that of patients with wild-type KRAS. These results warrant further studies re-examining the current policy restricting anti-EFGR therapies to patients with wild-type KRAS.
